NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-235-2015-0-EP-01 Methods for the Treatment of Kaposi's Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers EP National Stage 16815375.7 Issued
NCI E-014-2017-0-EP-05 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF EP National Stage 17835904.8 Issued
NCI E-014-2017-0-GB-01 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF GB EP 17835904.8 Issued
NCI E-014-2017-0-DE-01 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF DE EP 17835904.8 Issued
NCI E-014-2017-0-FR-01 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF FR EP 17835904.8 Issued
NIAID E-158-2007-3-US-05 LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE US DIV 15/850,696 10206995 Abandoned PDF
NCI E-014-2017-0-PCT-02 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF PCT PCT PCT/US2017/067974 Expired
NCI E-014-2017-0-EP-08 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF EP DIV 22209293.4 Pending
NCI E-230-2012-0-US-13 T CELL RECEPTORS RECOGNIZING MHC CLASS II-RESTRICTED MAGE-A3 US DIV 15/848,344 10611815 Issued PDF
NCATS E-115-2018-1-US-01 EMETINE COMPOUNDS AND COMBINATION THERAPY FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION US 62/608,347 Abandoned
NCI E-115-2017-0-JP-06 Azaindenoisoquinoline Compounds and Uses Thereof JP National Stage 2019-534676 Issued
NCI E-115-2017-0-PCT-02 Azaindenoisoquinoline Compounds and Uses Thereof PCT PCT PCT/US2017/067206 Expired
NCI E-115-2017-0-EP-05 Azaindenoisoquinoline Compounds and Uses Thereof EP National Stage 17882353.0 Pending
NCI E-115-2017-0-CA-03 Azaindenoisoquinoline Compounds and Uses Thereof CA National Stage 3047992 Pending
NLM E-110-2016-2-RU-08 Novel CRISPR Enzymes And Systems RU National Stage 2018101730 Issued
NLM E-111-2016-7-RU-08 Novel CRISPR Enzymes And Systems RU National Stage 2018101732 Issued
NCI E-188-2017-1-PCT-01 PEPTIDE HYDROGELS AND USE THEREOF PCT PCT PCT/US2017/066893 Expired
NCI E-115-2017-0-CN-04 Azaindenoisoquinoline Compounds and Uses Thereof CN National Stage 201780083073.3 Abandoned
NLM E-111-2016-9-US-01 NOVEL CRISPR ENZYMES AND SYSTEMS US CIP 15/844,530 114212502 Issued PDF
NCI E-130-2011-0-US-21 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR GLYPICAN-3 AND USE THEREOF US DIV 15/843,256 10640571 Issued PDF
NIAID E-174-2017-1-PCT-02 Protection Of Calves By A Prefusion-stabillze Bovine RSV Vaccine PCT PCT PCT/EP2017/083180 Expired
NIAID E-174-2017-1-EP-04 Protection Of Calves By A Prefusion-stabillze Bovine RSV Vaccine EP National Stage 17832216.0 Pending
NCI E-223-2017-0-US-01 CHEMICAL ENTITIES FOR LYTIC ACTIVATION OF KSHV AND THERAPEUTIC TARGETING OF VIRAL ENZYMES/PROTEINS US 62/598,807 Abandoned
NIAID E-174-2017-1-CA-03 Protection Of Calves By A Prefusion-stabillze Bovine RSV Vaccine CA National Stage 3043790 Pending
NCI E-289-2011-0-RU-21 YEAST-MUC1 IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF RU DIV 2017143985 Pending
NLM E-110-2016-3-US-01 Novel CRISPR Enzymes And Systems US CIP 15/842,073 111807512 Issued PDF
NCI E-019-2017-0-PCT-02 SHARPIN-BASED POLYPEPTIDES AND THEIR USES PCT PCT PCT/US2017/66463 Expired
NCATS E-276-2011-0-AU-10 Compounds And Methods For The Prevention And Treatment Of Tumor Metastasis And Tumorgenesis AU DIV 2017276258 Issued
NCI E-250-2016-0-PCT-02 METHODS OF PREPARING AN ISOLATED OR PURIFIED POPULATION OF THYMIC EMIGRANT CELLS AND METHODS OF TREATMENT USING SAME PCT PCT PCT/US2017/065986 Expired
NIAID E-209-2016-0-NZ-17 IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN ANTIBODY AGAINST RSV PREFUSION F PROTEIN NZ National Stage 738300 Abandoned
NIBIB E-143-2015-0-US-04 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF LONG-ACTING THERAPEUTICS US National Stage 15/735,687 10709790 Abandoned PDF
NCI E-151-2011-0-US-05 REDUCTION OF TGF BETA SIGNALING IN MYELOID CELLS IN THE TREATMENT OF CANCER US DIV 15/837,905 Abandoned
NINDS E-130-2022-3-HK-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE HK EP 62020005213.7 Issued
NINDS E-130-2022-3-EP-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE EP National Stage 17879038.2 Issued
NINDS E-130-2022-3-CN-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE CN National Stage 201780084881.1 Issued
NINDS E-130-2022-3-JP-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE JP National Stage 2019-530702 Issued
NINDS E-130-2022-3-MX-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE MX National Stage MX/a/2019/006694 Issued
NINDS E-130-2022-3-AU-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE AU National Stage 2017370731 Issued
NINDS E-130-2022-3-PC-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE PCT PCT COMB PCT/US2017/065270 Expired
NIA E-092-2011-0-US-10 THE USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)- KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN US CON 15/836,396 Abandoned
NIDA E-049-2015-0-US-04 METHOD AND SYSTEM FOR A MOBILE HEALTH PLATFORM US National Stage 15/580,975 Abandoned
NINDS E-130-2022-3-IN-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE IN National Stage 201917023002 Abandoned
NINDS E-130-2022-3-BR-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE BR National Stage 112019011627-3 Pending
NINDS E-130-2022-3-KR-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE KR National Stage 10-2019-7019763 Pending
NINDS E-130-2022-3-CA-01 OXABICYCLOHEPTANES FOR MODULATION OF IMMUNE RESPONSE CA National Stage 3046515 Pending
NCI E-240-2015-1-US-05 METHODS OF ANALYZING VIRUS-DERIVED THERAPEUTICS US National Stage 15/580,299 10662464 Issued PDF
NCI E-085-2013-0-JP-10 Methods of Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood JP DIV 2017-233698 Issued
NIDA E-073-2013-0-US-08 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF
MAKING; AND USE THEREOF 		US DIV 15/830,244 10590074 Issued PDF
NCI E-238-2017-0-US-01 METHODS OF ENRICHING CELL POPULATIONS FOR CANCER-SPECIFIC T CELLS USING IN VITRO STIMULATION OF MEMORY T CELLS US 62/594,262 Abandoned
NCI E-239-2017-0-US-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS US 62/594,244 Abandoned